Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7058824 | 1.00 | ALDH1A1 (0.32) | ALDH1A1LMNAKMT2AMAPTCYP3A4 | |
| SCHEMBL25475425 | 1.00 | ALDH1A1 (0.32) | ALDH1A1LMNAKMT2AMAPTCYP3A4 | |
| SCHEMBL8867224 | 0.90 | MMP2 (0.39) | ALDH1A1MAPTCYP3A4MMP2ANPEP | |
| SCHEMBL8866598 | 0.90 | MMP2 (0.39) | ALDH1A1MAPTCYP3A4MMP2ANPEP | |
| SCHEMBL3303917 | 0.88 | MEN1 (0.36) | ALDH1A1KMT2AMAPTCYP3A4TSHR | |
| SCHEMBL24166249 | 0.88 | MEN1 (0.36) | ALDH1A1KMT2AMAPTCYP3A4TSHR | |
| SCHEMBL6606249 | 0.87 | ALDH1A1 (0.34) | ALDH1A1LMNAKMT2AMAPTCYP3A4 | |
| SCHEMBL6611656 | 0.84 | ALDH1A1 (0.30) | ALDH1A1LMNAKMT2AMAPTCYP3A4 | |
| SCHEMBL6611658 | 0.84 | ALDH1A1 (0.30) | ALDH1A1LMNAKMT2AMAPTCYP3A4 | |
| SCHEMBL13390232 | 0.84 | TSHR (0.36) | MMP2ANPEPTSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939511-B2 | Contact lens treating method and composition | NOVARTIS AG (CH) | 2005-09-06 | — | — | US | claimed |
| US-20040071591-A1 | Contact lens treating method and composition | ALCON INC. (CH) | 2004-04-15 | — | — | US | claimed |
| US-6569824-B2 | Disinfecting with an aqueous solution containing an effective amount of a monoperphthalic acid compound in a given concentration | NOVARTIS AG (CH) | 2003-05-27 | — | — | US | claimed |
| US-20030078171-A1 | Contact lens treating method and composition | ALCON INC. (CH) | 2003-04-24 | — | — | US | claimed |
| EP-1255573-A1 | CONTACT LENS TREATING METHOD AND COMPOSITION | Novartis AG (CH) | 2002-11-13 | — | — | EP | claimed |
| WO-2001060421-A1 | CONTACT LENS TREATING METHOD AND COMPOSITION | NOVARTIS AG (CH) | 2001-08-23 | — | — | WO | claimed |
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | Sea Pharmaceuticals LLC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | MARTINEZ-PEREZ JOSE ANTONIO | 2010-04-15 | — | — | US | disclosed |
| EP-2166003-A1 | Excitatory amino acid receptor antagonists | Eli Lilly & Company (US) | 2010-03-24 | — | — | EP | disclosed |
| US-7601738-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1368032-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-06-11 | — | — | EP | disclosed |
| US-7205313-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | ARNOLD MACKLIN B | 2006-05-11 | — | — | US | disclosed |
| US-5356902-A | Central nervous system disorders | ELI LILLY AND COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| EP-0599518-A1 | Process and intermediates for the preparation of excitatory amino acide receptor antagonists | ELI LILLY AND COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0590789-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5284957-A | Substituted 1H- or 2H-tetrazoles | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| EP-0383504-A2 | Decahydro isoquinoline derivatives, process for their preparation and use as medicines | ELI LILLY AND COMPANY (US) | 1990-08-22 | — | — | EP | disclosed |
| CN-1044816-A | Improvements relating to organic compounds | LILLY CO ELI (US) | 1990-08-22 | — | — | CN | disclosed |
| US-4902695-A | ISOQUINOLINE DERIVATIVES; NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | GABRQ, GRIK5, CYP3A7 | ALDH1A1 501/4885LMNA 1938/4885KMT2A 1192/4885 |
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | SLC1A2, SLC1A1, GRIN1 | ALDH1A1 1633/4885LMNA 2973/4885KMT2A 1887/4885 |
| US-20060100237-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, GRIN1 | ALDH1A1 1633/4885LMNA 2973/4885KMT2A 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.